Agennix taps Lonza to produce talactoferrin

04/13/2012 | Genetic Engineering & Biotechnology News

Lonza agreed to commercially manufacture Agennix's talactoferrin, an oral dendritic-cell-mediated immunotherapy in late-stage trials as a therapy for nonsmall-cell lung cancer, at its microbial production plant in Kourim, Czech Republic. The deal initiates the process required for Lonza to be approved as a producer of talactoferrin.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC